Show simple item record

dc.contributor.authorSoto Cardenas, Maria Jose
dc.contributor.authorRuiz Sada, Pablo
dc.contributor.authorLópez Núñez, Juan J.
dc.contributor.authorSamperiz, Angel
dc.contributor.authorSoto Cardenas, María José 
dc.contributor.authorPedrajas Navas, Jose Maria
dc.contributor.authorPorras, José Antonio
dc.contributor.authorPeris, María Luisa
dc.contributor.authorDebourdeau, Philippe
dc.contributor.authorPace, Federica
dc.contributor.authorMonreal, Manuel
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2025-01-31T12:52:31Z
dc.date.available2025-01-31T12:52:31Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10498/35251
dc.description.abstractPatients with autoimmune disorders are at an increased risk of venous thromboembolism (VTE), but this association has not been consistently evaluated. We used the RIETE (Registro Informatizado Enfermedad Trombo Embo ́ lica) database to compare the rates of VTE recurrences, major bleeding, and death during the course of anticoagulation, according to the presence or absence of autoimmune disorders. Of 71 625 patients with VTE recruited in February 2018, 1800 (2.5%) had autoimmune disorders. Median duration of anticoagulant therapy was slightly longer in patients with autoimmune disorders (median, 190 vs 182 days; P ¼ .001). On multivariable analysis, patients with autoimmune disorders had a similar risk of VTE recurrences (hazard ratio [HR]: 0.93; 95% confidence interval [CI]: 0.68-1.27) or major bleeding (HR: 1.07; 95% CI: 0.82-1.40) and a lower risk to die (HR: 0.66; 95% CI: 0.54-0.81) than those without autoimmune disorders. Patients with giant cell arteritis had the highest rates of major bleeding (8.6 events per 100 patient-years) and the lowest rate of recurrences (zero). In other subgroups, the rates of both events were more balanced. During anticoagulation, patients with or without autoimmune disorders had similar rates of VTE recurrences or major bleeding. However, there were some differences between subgroups of patients with autoimmune disorders.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSagees_ES
dc.sourceAngiology. 2020 Feb;71(2):131-138.es_ES
dc.subjectautoimmune disorderses_ES
dc.subjectvenous thromboembolismes_ES
dc.subjectbleedinges_ES
dc.subjectrecurrenceses_ES
dc.subjectanticoagulant therapyes_ES
dc.titleVenous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry.es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1177/0003319719875895
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record